Description

McKesson’s $403 Billion Year: Can Oncology Growth Keep Driving The Upside?

The full-year fiscal 2026 performance of McKesson Corporation demonstrated solid growth across multiple segments, underpinned by strategic portfolio actions and operational efficiency. Consolidated revenues increased 12% to $403 billion, while adjusted operating profit grew 15% to $6.5 billion. Adjusted earnings per diluted share rose 18% to $39.11, exceeding the company’s long-term growth targets. This performance was supported by broad-based demand, particularly in specialty pharmaceutical distribution, oncology and multispecialty services, and prescription technology solutions, alongside disciplined expense management that improved operating leverage. Notably, the oncology and multispecialty segment experienced robust revenue growth of 35% with operating profit rising 53%, driven partly by strategic acquisitions such as PRISM Vision and Core Ventures, which have expanded provider networks and advanced community-based care capabilities. The North American Pharmaceutical segment saw a 3% revenue increase reflective of higher prescription volumes and specialty product strength, though partially offset by decreased branded pharmaceutical pricing.